Dr. Nedal Bukhari

Consultant in Medical Oncology at King
Fahad Specialist Hospital in Dammam Saudi Arabia,Clinical Assistant Professor at Imam Abdulrahman Bin
Faisal University in Dammam

09 : 35 – 09 : 45

24 June | 2023 Day 2

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk